Vaccination against equine influenza: Quid novi?
Equine influenza virus is a leading cause of respiratory disease in the horse. Equine influenza vaccines containing inactivated virus were first developed in the 1960s. Despite their intensive use, equine influenza outbreaks still continue to occur and therefore new strategies of vaccination are nec...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2006-05, Vol.24 (19), p.4047-4061 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4061 |
|---|---|
| container_issue | 19 |
| container_start_page | 4047 |
| container_title | Vaccine |
| container_volume | 24 |
| creator | Paillot, R. Hannant, D. Kydd, J.H. Daly, J.M. |
| description | Equine influenza virus is a leading cause of respiratory disease in the horse. Equine influenza vaccines containing inactivated virus were first developed in the 1960s. Despite their intensive use, equine influenza outbreaks still continue to occur and therefore new strategies of vaccination are necessary to improve vaccine efficacy. Numerous methods of vaccination have been evaluated and commercialised in the horse, the most recent being the cold-adapted influenza virus and poxvirus-based vaccines. As a large animal model, the horse is also a useful species in which to evaluate the potential of new generations of influenza vaccine such as live-attenuated influenza virus engineered by reverse genetics. This report details the equine immune responses conferring protection against influenza. It then undertakes a selective review of different strategies of vaccination against equine influenza that have been developed over the last two decades and discusses factors that may influence the efficacy of vaccination. Finally it outlines progress in the development of a novel vaccination strategy against equine influenza using reverse genetics. |
| doi_str_mv | 10.1016/j.vaccine.2006.02.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67945757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X06002143</els_id><sourcerecordid>17168248</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-47c7899a8b685dfc0575ec4a73f57deda1da215d4d5ced2360a7432b3911e3b83</originalsourceid><addsrcrecordid>eNqFkE1r3DAQQEVISTZpf0KCITQ3uzP6tHMJJfQLAqXQlt6EVpKDFq-cSPZC--ur7RoCveQ0lzdPmkfIBUKDgPLdptkZa0P0DQWQDdAGGByRFbaK1VRge0xWQCWvOcKvU3KW8wYABMPuhJyiFFwIUCsCP_9ZzBTGWJkHE2KeKv80F3EVYj_MPv4xN9W3Obgqjrtw-5q86s2Q_ZtlnpMfHz98v_tc33_99OXu_X1ty9tTzZVVbdeZdi1b4XoLQglvuVGsF8p5Z9AZisJxJ6x3lEkwijO6Zh2iZ-uWnZPrg_cxjU-zz5Pehmz9MJjoxzlrqTpenOpFEBXKlvK98eo_cDPOKZYjNAqusBRRe0ocKJvGnJPv9WMKW5N-awS9L683eimv9-U1UF3Kl73LxT6vt949by2pC_B2AUy2ZuiTiTbkZ04phZ2khbs9cL7U3QWfdLbBx1IpJG8n7cbwwlf-At3Doeg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547145578</pqid></control><display><type>article</type><title>Vaccination against equine influenza: Quid novi?</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Paillot, R. ; Hannant, D. ; Kydd, J.H. ; Daly, J.M.</creator><creatorcontrib>Paillot, R. ; Hannant, D. ; Kydd, J.H. ; Daly, J.M.</creatorcontrib><description>Equine influenza virus is a leading cause of respiratory disease in the horse. Equine influenza vaccines containing inactivated virus were first developed in the 1960s. Despite their intensive use, equine influenza outbreaks still continue to occur and therefore new strategies of vaccination are necessary to improve vaccine efficacy. Numerous methods of vaccination have been evaluated and commercialised in the horse, the most recent being the cold-adapted influenza virus and poxvirus-based vaccines. As a large animal model, the horse is also a useful species in which to evaluate the potential of new generations of influenza vaccine such as live-attenuated influenza virus engineered by reverse genetics. This report details the equine immune responses conferring protection against influenza. It then undertakes a selective review of different strategies of vaccination against equine influenza that have been developed over the last two decades and discusses factors that may influence the efficacy of vaccination. Finally it outlines progress in the development of a novel vaccination strategy against equine influenza using reverse genetics.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2006.02.030</identifier><identifier>PMID: 16545507</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Age Factors ; Animal models ; Animals ; Antibodies, Viral - biosynthesis ; Applied microbiology ; Bacterial infections ; Biological and medical sciences ; Equine influenza virus ; Female ; Fundamental and applied biological sciences. Psychology ; Genetic Vectors ; Genetics ; Horse Diseases - immunology ; Horse Diseases - prevention & control ; Horse species ; Horses ; Immune system ; Immunity, Cellular ; Immunity, Maternally-Acquired ; Influenza ; Influenza A Virus, H3N8 Subtype - classification ; Influenza A Virus, H3N8 Subtype - genetics ; Influenza A Virus, H3N8 Subtype - immunology ; Influenza Vaccines - genetics ; Influenza Vaccines - pharmacology ; Microbiology ; Models, Immunological ; Molecular Epidemiology ; Orthomyxoviridae Infections - immunology ; Orthomyxoviridae Infections - prevention & control ; Orthomyxoviridae Infections - veterinary ; Pregnancy ; Respiratory diseases ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Attenuated - pharmacology ; Vaccines, DNA - genetics ; Vaccines, DNA - pharmacology ; Vaccines, Inactivated - pharmacology ; Vaccines, Subunit - genetics ; Vaccines, Subunit - pharmacology ; Vaccines, Synthetic - genetics ; Vaccines, Synthetic - pharmacology</subject><ispartof>Vaccine, 2006-05, Vol.24 (19), p.4047-4061</ispartof><rights>2006 Elsevier Ltd</rights><rights>2006 INIST-CNRS</rights><rights>Copyright Elsevier Limited May 8, 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-47c7899a8b685dfc0575ec4a73f57deda1da215d4d5ced2360a7432b3911e3b83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X06002143$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17771962$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16545507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paillot, R.</creatorcontrib><creatorcontrib>Hannant, D.</creatorcontrib><creatorcontrib>Kydd, J.H.</creatorcontrib><creatorcontrib>Daly, J.M.</creatorcontrib><title>Vaccination against equine influenza: Quid novi?</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Equine influenza virus is a leading cause of respiratory disease in the horse. Equine influenza vaccines containing inactivated virus were first developed in the 1960s. Despite their intensive use, equine influenza outbreaks still continue to occur and therefore new strategies of vaccination are necessary to improve vaccine efficacy. Numerous methods of vaccination have been evaluated and commercialised in the horse, the most recent being the cold-adapted influenza virus and poxvirus-based vaccines. As a large animal model, the horse is also a useful species in which to evaluate the potential of new generations of influenza vaccine such as live-attenuated influenza virus engineered by reverse genetics. This report details the equine immune responses conferring protection against influenza. It then undertakes a selective review of different strategies of vaccination against equine influenza that have been developed over the last two decades and discusses factors that may influence the efficacy of vaccination. Finally it outlines progress in the development of a novel vaccination strategy against equine influenza using reverse genetics.</description><subject>Age Factors</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Applied microbiology</subject><subject>Bacterial infections</subject><subject>Biological and medical sciences</subject><subject>Equine influenza virus</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetic Vectors</subject><subject>Genetics</subject><subject>Horse Diseases - immunology</subject><subject>Horse Diseases - prevention & control</subject><subject>Horse species</subject><subject>Horses</subject><subject>Immune system</subject><subject>Immunity, Cellular</subject><subject>Immunity, Maternally-Acquired</subject><subject>Influenza</subject><subject>Influenza A Virus, H3N8 Subtype - classification</subject><subject>Influenza A Virus, H3N8 Subtype - genetics</subject><subject>Influenza A Virus, H3N8 Subtype - immunology</subject><subject>Influenza Vaccines - genetics</subject><subject>Influenza Vaccines - pharmacology</subject><subject>Microbiology</subject><subject>Models, Immunological</subject><subject>Molecular Epidemiology</subject><subject>Orthomyxoviridae Infections - immunology</subject><subject>Orthomyxoviridae Infections - prevention & control</subject><subject>Orthomyxoviridae Infections - veterinary</subject><subject>Pregnancy</subject><subject>Respiratory diseases</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Attenuated - pharmacology</subject><subject>Vaccines, DNA - genetics</subject><subject>Vaccines, DNA - pharmacology</subject><subject>Vaccines, Inactivated - pharmacology</subject><subject>Vaccines, Subunit - genetics</subject><subject>Vaccines, Subunit - pharmacology</subject><subject>Vaccines, Synthetic - genetics</subject><subject>Vaccines, Synthetic - pharmacology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE1r3DAQQEVISTZpf0KCITQ3uzP6tHMJJfQLAqXQlt6EVpKDFq-cSPZC--ur7RoCveQ0lzdPmkfIBUKDgPLdptkZa0P0DQWQDdAGGByRFbaK1VRge0xWQCWvOcKvU3KW8wYABMPuhJyiFFwIUCsCP_9ZzBTGWJkHE2KeKv80F3EVYj_MPv4xN9W3Obgqjrtw-5q86s2Q_ZtlnpMfHz98v_tc33_99OXu_X1ty9tTzZVVbdeZdi1b4XoLQglvuVGsF8p5Z9AZisJxJ6x3lEkwijO6Zh2iZ-uWnZPrg_cxjU-zz5Pehmz9MJjoxzlrqTpenOpFEBXKlvK98eo_cDPOKZYjNAqusBRRe0ocKJvGnJPv9WMKW5N-awS9L683eimv9-U1UF3Kl73LxT6vt949by2pC_B2AUy2ZuiTiTbkZ04phZ2khbs9cL7U3QWfdLbBx1IpJG8n7cbwwlf-At3Doeg</recordid><startdate>20060508</startdate><enddate>20060508</enddate><creator>Paillot, R.</creator><creator>Hannant, D.</creator><creator>Kydd, J.H.</creator><creator>Daly, J.M.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20060508</creationdate><title>Vaccination against equine influenza: Quid novi?</title><author>Paillot, R. ; Hannant, D. ; Kydd, J.H. ; Daly, J.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-47c7899a8b685dfc0575ec4a73f57deda1da215d4d5ced2360a7432b3911e3b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Age Factors</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Applied microbiology</topic><topic>Bacterial infections</topic><topic>Biological and medical sciences</topic><topic>Equine influenza virus</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetic Vectors</topic><topic>Genetics</topic><topic>Horse Diseases - immunology</topic><topic>Horse Diseases - prevention & control</topic><topic>Horse species</topic><topic>Horses</topic><topic>Immune system</topic><topic>Immunity, Cellular</topic><topic>Immunity, Maternally-Acquired</topic><topic>Influenza</topic><topic>Influenza A Virus, H3N8 Subtype - classification</topic><topic>Influenza A Virus, H3N8 Subtype - genetics</topic><topic>Influenza A Virus, H3N8 Subtype - immunology</topic><topic>Influenza Vaccines - genetics</topic><topic>Influenza Vaccines - pharmacology</topic><topic>Microbiology</topic><topic>Models, Immunological</topic><topic>Molecular Epidemiology</topic><topic>Orthomyxoviridae Infections - immunology</topic><topic>Orthomyxoviridae Infections - prevention & control</topic><topic>Orthomyxoviridae Infections - veterinary</topic><topic>Pregnancy</topic><topic>Respiratory diseases</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Attenuated - pharmacology</topic><topic>Vaccines, DNA - genetics</topic><topic>Vaccines, DNA - pharmacology</topic><topic>Vaccines, Inactivated - pharmacology</topic><topic>Vaccines, Subunit - genetics</topic><topic>Vaccines, Subunit - pharmacology</topic><topic>Vaccines, Synthetic - genetics</topic><topic>Vaccines, Synthetic - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paillot, R.</creatorcontrib><creatorcontrib>Hannant, D.</creatorcontrib><creatorcontrib>Kydd, J.H.</creatorcontrib><creatorcontrib>Daly, J.M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paillot, R.</au><au>Hannant, D.</au><au>Kydd, J.H.</au><au>Daly, J.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccination against equine influenza: Quid novi?</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2006-05-08</date><risdate>2006</risdate><volume>24</volume><issue>19</issue><spage>4047</spage><epage>4061</epage><pages>4047-4061</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Equine influenza virus is a leading cause of respiratory disease in the horse. Equine influenza vaccines containing inactivated virus were first developed in the 1960s. Despite their intensive use, equine influenza outbreaks still continue to occur and therefore new strategies of vaccination are necessary to improve vaccine efficacy. Numerous methods of vaccination have been evaluated and commercialised in the horse, the most recent being the cold-adapted influenza virus and poxvirus-based vaccines. As a large animal model, the horse is also a useful species in which to evaluate the potential of new generations of influenza vaccine such as live-attenuated influenza virus engineered by reverse genetics. This report details the equine immune responses conferring protection against influenza. It then undertakes a selective review of different strategies of vaccination against equine influenza that have been developed over the last two decades and discusses factors that may influence the efficacy of vaccination. Finally it outlines progress in the development of a novel vaccination strategy against equine influenza using reverse genetics.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16545507</pmid><doi>10.1016/j.vaccine.2006.02.030</doi><tpages>15</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2006-05, Vol.24 (19), p.4047-4061 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67945757 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Age Factors Animal models Animals Antibodies, Viral - biosynthesis Applied microbiology Bacterial infections Biological and medical sciences Equine influenza virus Female Fundamental and applied biological sciences. Psychology Genetic Vectors Genetics Horse Diseases - immunology Horse Diseases - prevention & control Horse species Horses Immune system Immunity, Cellular Immunity, Maternally-Acquired Influenza Influenza A Virus, H3N8 Subtype - classification Influenza A Virus, H3N8 Subtype - genetics Influenza A Virus, H3N8 Subtype - immunology Influenza Vaccines - genetics Influenza Vaccines - pharmacology Microbiology Models, Immunological Molecular Epidemiology Orthomyxoviridae Infections - immunology Orthomyxoviridae Infections - prevention & control Orthomyxoviridae Infections - veterinary Pregnancy Respiratory diseases Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Attenuated - pharmacology Vaccines, DNA - genetics Vaccines, DNA - pharmacology Vaccines, Inactivated - pharmacology Vaccines, Subunit - genetics Vaccines, Subunit - pharmacology Vaccines, Synthetic - genetics Vaccines, Synthetic - pharmacology |
| title | Vaccination against equine influenza: Quid novi? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T15%3A50%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccination%20against%20equine%20influenza:%20Quid%20novi?&rft.jtitle=Vaccine&rft.au=Paillot,%20R.&rft.date=2006-05-08&rft.volume=24&rft.issue=19&rft.spage=4047&rft.epage=4061&rft.pages=4047-4061&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2006.02.030&rft_dat=%3Cproquest_cross%3E17168248%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1547145578&rft_id=info:pmid/16545507&rft_els_id=S0264410X06002143&rfr_iscdi=true |